Press coverage about Omnicell (NASDAQ:OMCL) has been trending somewhat positive on Sunday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omnicell earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.4216400842992 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Zacks: Analysts Expect Omnicell, Inc. (OMCL) to Post $0.20 EPS (americanbankingnews.com)
- Shares of OMCL Up 39.8% Since Uptrend Call on Shares (mysmartrend.com)
- Omnicell, Inc. (NASDAQ:OMCL) VP Peter J. Kuipers Sells 18,054 Shares (americanbankingnews.com)
- Omnicell, Inc. (NASDAQ:OMCL) VP Sells $581,945.00 in Stock (americanbankingnews.com)
- Omnicell, Inc. (OMCL) VP Sells $1,056,254.62 in Stock (americanbankingnews.com)
Omnicell (NASDAQ OMCL) opened at 50.10 on Friday. The firm’s market capitalization is $1.88 billion. Omnicell has a one year low of $30.35 and a one year high of $51.98. The firm has a 50-day moving average price of $45.37 and a 200 day moving average price of $41.17.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 earnings per share. Equities research analysts anticipate that Omnicell will post $1.31 earnings per share for the current year.
A number of equities research analysts have weighed in on the company. BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and set a $40.00 price target on shares of Omnicell in a research note on Sunday, July 30th. Cantor Fitzgerald reissued a “buy” rating and set a $47.00 price target on shares of Omnicell in a research note on Tuesday, July 25th. Dougherty & Co boosted their price target on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Craig Hallum boosted their price target on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $49.00.
In other Omnicell news, Director Gary S. Petersmeyer sold 2,200 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $41.41, for a total transaction of $91,102.00. Following the sale, the director now directly owns 21,075 shares of the company’s stock, valued at $872,715.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter J. Kuipers sold 18,054 shares of the company’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $50.31, for a total transaction of $908,296.74. Following the sale, the vice president now directly owns 44,236 shares in the company, valued at $2,225,513.16. The disclosure for this sale can be found here. In the last three months, insiders sold 199,823 shares of company stock worth $9,301,391. 3.77% of the stock is currently owned by insiders.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.